Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement
| 대상 질환 | Degenerative Arthritis, Rheumatoid Arthritis, Traumatic Arthritis |
|---|---|
| 임상 단계 | 단계 해당 없음 |
| 스폰서 | Smith & Nephew, Inc. |
| 상태 | 조기 종료 |
| 참여자 수 | 65 명 |
| 중재(약물) | Implantation of Integra Cadence Total Ankle System |
| 시작일 | 2017년 9월 18일 |
| 완료일 | 2023년 9월 6일 |
| 결과 공개일 | 2026년 6월 22일 |
요약
This study will evaluate the long term performance and safety data for the Cadence™ Total Ankle System (CTAS) when used for primary arthroplasty in patients with primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), and systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis)
Implant Survivorship at 2 Years
| Integra® Cadence™ Total Ankle System | 100 percentage of participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Dietary Salt in Rheumatoid Arthritis — Vanderbilt University Medical Center
- Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) — University of North Carolina, Chapel Hill
- Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
- CD40L Antagonism in Rheumatoid Arthritis (RA) — National Institute of Allergy and Infectious Diseases (NIAID)
- A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Eli Lilly and Company